Cogas Consulting, LLC
525 Oakhaven Drive, Suite 100
Roswell, GA 30075
About Cogas Consulting, LLC
Cogas was founded to support pharma, biotech and medical device companies when
- attempting to identify and assess potential assets for acquisitions and/or divestment
- assembling strategic development plans for your assets in order to make them more attractive to future potential partners
- establishing partnering arrangements (in-license, out-license, co-development)
- performing technical due diligence (preclinical, CMC, clinical)
Proper identification and management of developmental risk is essential in negotiating and implementing an agreement which works for all parties concerned. We can provide valuable insights into current trends in the industry to assist in establishing terms, expectations, valuations and the competitive landscape.
Interested in learning more?
"An experienced business development professional is more than a good negotiator in possession of a large contact database"
John W. Sharkey, Ph.D. - President
Dr. Sharkey is a global healthcare professional with expertise in the development and partnering of global pharmaceutical and medical device products. With demonstrated successes within large multinational, midsize specialty and start-up company environments, he routinely assists his clients in overcoming obstacles while maintaining alignment with their strategic objectives.
Prior to forming Cogas Consulting, Dr. Sharkey served as the EVP - BD&L and Alliance Management for Shionogi Pharmaceuticals where he headed the group responsible for all activities related to identifying, assessing and managing partnering opportunities, M&A, licensing, divestment and alliance management. Prior to Shionogi Pharma's (Osaka, Japan) 2009 acquisition of Sciele Pharmaceuticals, he served as Sciele's VP of BD&L. Dr. Sharkey previously spent 16 years with Novartis Pharmaceuticals in increasing positions of responsibility within pharmaceutical and technical development as well as business development, eventually being appointed VP, BD&L for the Ophthalmic Business Unit.
Dr. Sharkey has been the lead, or a critical contributor, to several notable partnering transactions over the years including Novartis’ ex-US license with Genentech for Lucentis®, the transactions with Celgene and Elan for Focalin® as well as Shionogi’s global license for Osphena®. He has also assisted several companies in their financing activities over the years.
With experience across several therapeutic areas including CV, Metabolism, Ophthalmology, Pediatrics, Pulmonary, Renal, Woman's Health and Urology, he understands your company's unique situation and requirements.
•Globally Experienced – Dr. Sharkey has held key leadership roles for ex-US headquartered multinationals •Company Balanced – He is experienced in all size companies, from Fortune 100 to start-ups •Consistency – Dr Sharkey has a history of producing results and overcoming hurdles. He has led teams which
successfully resolved development, regulatory and manufacturing issues around several important development assets. He successfully renegotiated several troubled collaborations to expand rights and prevent loss of development assets.
•Collaborative – Dr Sharkey consistently work across development and commercial organizations to achieve company objectives and break down silos
•Cross-Functional – Experience in Corporate and Business Development, M&A, Licensing, Alliance Management, Strategy, Operations, Pharmaceutical and Medical Device Development, Preclinical Development, Clinical Development, Drug Delivery and Regulatory.
facilitating growth through effective partnering